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ABSTRACT
A plateau in long-term survival patterns of patients undergoing blood and marrow transplantation (BMT) from
allogeneic donors is apparent, but whether their expected survival ever parallels that of the normative
population is unclear. This study attempts to identify a cutoff time for classifying BMT patients as long-term
survivors and compares their actual survival with the expected survival of an age- and gender-matched
“normal” population. In this study, the records of 1386 patients who underwent allogeneic BMT at Princess
Margaret Hospital between 1970 and 2002 were reviewed. Hazard rates (HRs), Kaplan-Meier survival esti-
mates, and loess curves were used to propose a cutoff time classifying patients as long-term survivors. Factors
predictive of overall survival and survival for long-term survivors were investigated. Actual survival for these
patients was compared with the expected survival of the Canadian “normal” population. A cutoff time of 6 years
post-BMT was proposed to define long-term survivors based on loess curves of hazard ratios and yearly
survival statistics. The only statistically significant predictor of survival among long-term survivors was having
a male donor (HR  0.39; 95% confidence interval [CI]  0.17–0.88). Although only 62% of patients survived
the first year post-BMT, 98.5% of patients alive after 6 years survived at least another year. Almost 1/3 (31%)
of the deaths in long-term survivors resulted from causes unrelated to transplantation or relapse. The observed
number of deaths among BMT patients exceeded the expected number from the Canadian population;
however, the difference in life expectancy decreased the longer that a patient survived. The 95% CIs for the
observed/expected number of deaths cover 1, indicative of no difference, after the tenth year post-BMT.
A cutoff of 6 years is proposed to define long-term survivorship after BMT. Life expectancy remained reduced
compared with that of the “normal” population; however, this difference decreased the longer that a patient
survived. Known risk factors of short-term survival disappeared, with only donor gender predictive of survival
among long-term survivors.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Blood and marrow transplantation (BMT) from
llogeneic donors has become an established thera-
eutic option for patients with a variety of otherwise
atal blood disorders. Despite recent improvements in
echnique, however, the procedure remains associated
ith considerable transplantation-related risks, as well
s failure to control the underlying disease. The con-
ributions to outcome by such risk factors as disease
tatus at BMT, donor match, and graft-versus-host t
22isease (GvHD) to early mortality are well recognized
1-3]; however, whether the inﬂuence of these factors
emains constant over time or is time-restricted re-
ains unclear. Survival analyses usually focus on risks
hat determine the probability of early events before
tabilization of survival curves. The long-term survival
atterns of patients on an apparent plateau are not
ell established, and whether the mortality rates of
ong-term survivors ever return to that of the norma-
ive population is unclear.
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Long-Term Survival after Blood and Marrow Transplantation
BSome of these questions have been addressed by
tudies on long-term survivors reported to the Inter-
ational Bone Marrow Transplant Registry (IBMTR)
nd European Bone Marrow Transplant Registry
EBMT). Socie et al. [4] investigated the long-term
urvival and late deaths after allogeneic BMT of all
atients reported to the IBMTR who survived at least
years after transplantation. The mortality in these
atients was higher than that in the normal popula-
ion; causes of death were commonly related to relapse
r GvHD. A rationale was not provided for the choice
f a 2-year cutoff to deﬁne long-term survivors, and
o indication was given as to whether or not the
ortality rate continued to improve over time. Duell
t al. [5] reported on the health and functional status
f long-term survivors in European BMT patients,
hoosing 5 years as the cutoff deﬁnition for a long-
erm survivor. Again, no justiﬁcation was given for this
hoice of 5 years. Most of the patients were in good
ealth and had returned to full-time work or school.
he leading causes of death among these long-term
urvivors were disease recurrence, chronic GvHD,
ung disease, secondary malignancies, and infections
econdary to a persisting immune deﬁciency.
Using a database on 1387 consecutive patients
ho underwent transplantation at a single center, we
xplored whether or not the mortality rate of BMT
ecipients ever returned to equal that of the normal
opulation. To classify patients as long-term survi-
ors, we estimated the time point at which the risk of
ying after the transplantation had stabilized. Known
redictors of short-term mortality and their effect on
urvival of long-term survivors were examined. The
ortality rate of long-term survivors was then com-
ared with that of the normal age- and gender-ad-
usted Canadian population.
ATIENTS AND METHODS
atients
The records of all 1387 patients who received an
llogeneic BMT at our institution between 1970 and
002 were reviewed. One patient refused permission
o use his medical record for research purposes; this
tudy includes the records of the remaining 1386 pa-
ients.
tatistical Methods
Descriptive statistics, including mean, standard
eviation, frequency, and proportions, were used to
ssess such characteristics as patient age, disease status
t time of BMT, donor status, and diagnosis. The
atabase was updated with respect to survival data for
ll registered patients as of December 31, 2002. All
atients known to be alive were censored for survival
n that date, and survival estimates were calculated m
B&MTsing the Kaplan-Meier method [6]. Hazard rates
HRs) estimating the risk of a patient dying were
alculated for time intervals of consistent length post-
MT, and loess smoothers [7] were applied to hazard
lots. A loess curve takes a small window of data and
lots the average HR in that window; in this study, a
indow of 45 days was applied. The window is then
hifted to encompass the next 45 days, and the average
s recalculated and plotted. This is repeated, and the
oints are connected, forming a curve representing
he average HR across time, clearly showing changes
n the HR over time.
Multiple plots were constructed using time inter-
als of different lengths and different loess smoothing
arameters. Based on visual inspection of these plots
nd examination of local extrema in yearly HRs and
onditional survival statistics, a cutoff time was pro-
osed such that patients who survived past the cutoff
ere classiﬁed as long-term survivors. Univariate Cox
roportional hazards models [8] were used to evaluate
hether or not risk factors determined at the time of
ransplantation that were predictive of survival in the
arly post-BMT period also contributed to survival of
atients deﬁned as long-term survivors.
The survival rate of long-term BMT survivors was
ompared with that of the Canadian “normal” popu-
ation. For each year in the period 1970-2002, the
otal number of patient-years of follow-up of survivors
as calculated, grouped by gender and age using
AMCOMP 1.41 [9]. Five-year age intervals (eg,
0–14 years, 15–19 years) were used for the age
roupings. The age- and gender-adjusted mortality
ate for each year for all Canadians was obtained from
tatistics Canada annual reports (catalogue no. 84-209
or the 1991-2002 data and catalogue no. 82-548 for
he 1970-1990 data). The number of patient-years was
ultiplied by the mortality rate for each respective
ategory, yielding the expected number of deaths. The
xpected number of deaths for each category was
ummed to obtain an overall expected number of
eaths. The observed number of deaths in this patient
ample on or before December 31, 2002 was divided
y the expected number of deaths to obtain the ob-
erved/expected ratio, and exact 95% conﬁdence in-
ervals (CIs) were calculated in PAMCOMP 1.41. All
ests were 2-sided, and any P value  .05 was consid-
red statistically signiﬁcant. Approval for this retro-
pective data analysis was obtained from the Princess
argaret Hospital Research Ethics Board.
ESULTS
Descriptive statistics of all patients are summa-
ized in Table 1. The mean patient age at BMT was
8.4 years, and 57% of the study group was male. The
ajority of patients were diagnosed with either
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4hronic myelocytic leukemia (31%) or acute myelo-
ytic leukemia (29%). Some 54% of the patients had a
ale donor, 56% were the same gender as their do-
or, and 75% of the donors were HLA-identical sib-
ings. Based on the institutional policy for patients
ndergoing transplantation for different diseases and
isease states, the majority of patients underwent
ransplantation using the following preparative regi-
ens: (1) cytosine arabinoside 100 mg/m2/day  5
ays, cyclophosphamide (CTX) 60 mg/kg/day  2
ays, and total body irradiation (TBI) 500 cGy as a
ingle fraction (n  453 [32.7%]); (2) CTX 60 mg/
able 1. Descriptive Statistics of BMT Patients
Variable
All
Patients
(n  1386)
Patients
Who
Survived
>6 Years
(n  368)
ean (SD) age 38.4 (11.8) 34.4 (10.0)
(%) male 783 (56.5) 206 (56.0)
(%) with male donor* 747 (54.0) 209 (56.8)
(%) with a gender matched donor* 768 (55.5) 213 (57.9)
(%) Diagnosis
ALL 181 (13.1) 37 (10.1)
AML 397 (28.6) 105 (28.5)
CLL 31 (2.2) 2 (0.5)
CML 428 (30.9) 137 (37.2)
Other 349 (25.2) 87 (23.6)
onor type
HLA-identical sibling 1035 (74.7) 313 (85.1)
Syngeneic 24 (1.7) 10 (2.7)
Other related HLA†-matched 23 (1.7) 5 (1.4)
Related 1 Ag mismatched 90 (2.6) 15 (2.2)
Related > 2 Ag mismatched 4 (0.1) 0 (0)
Unrelated donor HLA-matched 193 (13.9) 25 (6.8)
Unrelated donor HLA-mismatched 17 (1.2) 0 (0)
tatus at BMT
First remission (AML, ALL) 335 (24.2) 100 (27.2)
Other than first remission (AML,
ALL) 230 (16.6) 41 (11.1)
First chronic phase (CML) 280 (20.2) 104 (28.3)
Other than first chronic phase
(CML) 150 (10.8) 33 (9.0)
Other 13 (0.9) 3 (0.8)
Unknown 378 (27.3) 87 (23.6)
reparative regimen‡
CA  CY  TBI 453 (32.7) 180 (48.9)
CY  fTBI 386 (27.8) 49 (13.3)
BU  CY 336 (24.2) 80 (21.7)
Other 211 (15.2) 59 (16.0)
(%) alive at last follow-up 670 (48.3) 342 (92.9)
Information on donor gender was unavailable on 2 BMT patients,
neither of whom survived 6 years.
HLA match is deﬁned on the basis of A, B, and DR.
CA, cytosine arabinoside 100 mg/m2/day  5 days; CY, cyclo-
phosphamide 60 mg/kg/day  2 days; TBI, total body irradia-
tion 500 cGY/single fraction; fTBI, fractionated total body
irradiation at 200 cGy  6 doses over 3 days; BU, busulfan
4 mg/kg/day  4 days; AML, acute myelocytic leukemia; ALL,
acute lymphocytic leukemia; CML, chronic myelocytic leukemia;
CLL, chronic lymphocytic leukemia.g/day  2 days (3 days in some cases) and fraction- a
24ted TBI at 200 cGy  6 doses over 3 days (n  386
27.8%]); and (3) busulfan 4 mg/kg/day  4 days and
TX 60 mg/kg/day  2 days (n  336 [24.2%]). The
emaining 211 patients (15.2%) were prepared with
arious other regimens (not shown). Patients under-
oing transplantation after September 10, 1986 re-
eived GvHD prophylaxis with cyclosporin and could
e treated with ganciclovir for cytomegalovirus (CMV)-
elated complications. Some 48% of the patients were
live as of December 31, 2002; a total of 368 (27%)
atients were known to be alive beyond 6 years after
MT.
Figure 1 depicts a Kaplan-Meier survival plot with
5% CIs for all of the transplantation patients. Numer-
us patients died shortly after BMT, as indicated by
he steep initial slope of the survival curve. With
ncreasing time after transplantation, the survival curve
attened and the probability of patient survival in-
reased, as shown in Table 2, for conditional survival
or each year. Some 62% of BMT patients survived at
east 365 days, and of those surviving 365 days, 89%
urvived at least another 365 days. Of the patients who
urvived 6 years post-BMT, 98.5% survived at least
nother year.
The HR is deﬁned as the probability that a patient
ill die shortly after a deﬁned time point given that he
r she has survived up to that time. Table 2 gives the
Rs of death for the mid point of each year post-
MT. For instance, the probability of a patient dying
n day 182 post-BMT given that he or she survived
he ﬁrst 181 days is 0.001293, and the probability of a
atient dying on day 548 post-BMT (midpoint of year
–2) given that he or she survived the ﬁrst 547 days is
.000307. Note that the 95% CI for the HR reaches
ear 0 for the ﬁrst time in year 6-7 post-BMT.
HRs were estimated for various sequential time
ntervals, and a loess smoother was used to calculate a
eighted average for each time point. This method
ives estimated HRs over time. Figure 2 provides a
epresentative graph in which HRs are estimated for
5-day follow-up intervals. Plots using different inter-
als had similar shapes (data not shown). In Figure 2,
he HR was estimated for the 23rd day of each inter-
al, and a loess smoother was applied using the loess
unctions with a smoothing parameter span of 0.1. As
an be seen, the HR dropped to near 0 around 6 years
ost-BMT and leveled off at around 10 years. The HR
years post-BMT was similar for patients undergoing
ransplantation before (0.0001) and after (0.00006) the
vailability of cyclosporin and ganciclovir. Thus, 6
ears was chosen as the time cutoff point deﬁning
ong-term survivors.
The effect of selected risk parameters deter-
ined at BMT on survival for all patients and for
ong-term survivors is described in Table 3. Diag-
osis, status at BMT, a gender-matched donor, and
n HLA-matched donor were all statistically signiﬁ-
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Long-Term Survival after Blood and Marrow Transplantation
Bant predictors of overall survival. Only donor gender
as a statistically signiﬁcant predictor of long-term
urvival beyond 6 years. Having a male donor de-
reased the HR rate by an estimated 0.39 times (95%
I  0.17–0.88) for these patients. Sixteen of the 143
ong-term BMT survivors who had a female donor are
nown to have died, compared with 9 of the 198
ong-term BMT survivors who had a male donor. All
1 patients with AML or acute lymphocytic leukemia
xperiencing more than 1 remission, as well as both
hronic lymphocytic leukemia patients, who survived
years were alive at last follow-up; thus, no propor-
ional hazards estimate could be made for these vari-
bles. The choice of the preparative regimen had no
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Figure 1. Overall survival with 95% CIs of all 1386 p
able 2. Survival Statistics by Year of Follow-Up
Days Years
Patients
Alive at
Year Start
Number of
Deaths
(716)
Numbe
Censore
(670)
-365 0-1 1386 517 75
66-730 1-2 794 82 43
31-1095 2-3 669 36 46
096-1460 3-4 587 31 72
461-1825 4-5 484 15 52
826-2190 5-6 417 9 40
191-2555 6-7 368 5 45
556-2920 7-8 318 9 32
921-3285 8-9 277 3 34
286-3650 9-10 240 4 31
651-4015 10-11 205 0 34
016-4380 11-12 171 1 27
381-4745 12-13 143 1 24
746-5110 13-14 118 0 19
111-5475 14-15 99 1 21
476- 15- 77 2 75
B&MTmpact on the survival of patients living beyond 6 years
P  .27; Figure 3).
To compare the mortality rate of long-term sur-
ivors with that of the Canadian normal population,
he number of patient-years of follow-up at least
years post-BMT was calculated. There were 26
ong-term survivors who died in 2092.49 patient-
ears. The expected number of deaths in the same
ollow-up period is 4.6855, resulting in an estimated
bserved/expected ratio of 5.55 (95% CI  3.62–
.13). Table 4 gives the observed/expected ratios by
ear post-BMT, and Figure 4 displays this informa-
ion visually. This plot shows the mortality rate and
espective 95% CI for BMT patients by year after
 after BMT
20 25 30
undergoing transplantation between 1970 and 2002.
Estimated HR at
the Middle Time
(104) (95% CI)
Overall Survival
(95% CI)
One-Year
Conditional
Survival (95% CI)
12.93 (11.85, 14.02) 61.8 (59.2, 64.4) 61.8 (59.2, 64.4)
3.07 (2.41, 3.73) 55.3 (52.6, 58.0) 89.4 (87.3, 91.6)
1.57 (1.06, 2.08) 52.2 (49.5, 54.9) 94.4 (92.7, 96.2)
1.59 (1.03, 2.14) 49.2 (46.5, 52.0) 94.3 (92.4, 96.3)
0.91 (0.45, 1.37) 47.7 (44.9, 50.4) 96.8 (95.2, 98.4)
0.63 (0.22, 1.04) 46.6 (43.8, 49.4) 97.7 (96.3, 99.2)
0.40 (0.05, 0.75) 45.9 (43.1, 48.7) 98.5 (97.2, 99.8)
0.83 (0.29, 1.37) 44.5 (41.6, 47.4) 97.0 (95.1, 98.9)
0.32 (0.00, 0.68) 44.0 (41.1, 46.9) 98.9 (97.6, 100.0)
0.49 (0.01, 0.98) 43.2 (40.3, 46.2) 98.2 (96.5, 100.0)
0.00 (—, —) 43.2 (40.3, 46.2) 100.0 (—, —)
0.17 (0.00, 0.52) 43.0 (40.0, 45.9) 99.4 (98.2, 100.0)
0.21 (0.00, 0.62) 42.7 (39.6, 45.7) 99.3 (97.9, 100.0)
0.00 (—, —) 42.7 (39.6, 45.7) 100.0 (—, —)
0.31 (0.00, 0.92) 42.1 (39.0, 45.3) 98.7 (96.3, 100.0)Years
15r
d— — —
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4ransplantation compared with the Canadian age- and
ender-adjusted normal population, indicated by the
orizontal line. The horizontal line represents an ob-
erved/expected ratio of 1 consistent with the point at
hich there is no increased mortality risk. The ratio
xceeds 1 for each year post-BMT, indicating that the
bserved number of deaths in this population is sig-
iﬁcantly greater than expected for the normal popu-
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Figure 2. Loess curve of HRs divided by c
able 3. Univariate Predictors of Long-Term Conditional Survival
Variable
Hazard Ratio (95% CI)
All Patients
Patients
Surviving
6  Years
ge (/10 years) 1.05 (0.98, 1.12) 1.02 (0.67, 1.55)
ale 0.91 (0.79, 1.06) 0.97 (0.45, 2.10)
ale donor 1.00 (0.86, 1.16) 0.39 (0.17, 0.88)
onor gender match 0.85 (0.73, 0.98) 1.04 (0.48, 2.27)
iagnosis
ALL 1.33 (1.08, 1.63) 0.28 (0.04, 2.06)
AML 1.17 (1.00, 1.37) 0.88 (0.37, 2.11)
CLL 1.12 (0.68, 1.84) Insufficient Data
CML 0.72 (0.61, 0.85) 1.32 (0.60, 2.87)
Other 1.01 (0.85, 1.20) 1.34 (0.56, 3.19)
LA-identical sibling 0.55 (0.47, 0.64) 1.71 (0.40, 7.27)
tatus at BMT
First remission (AML,
ALL) 0.83 (0.70, 0.99) 1.07 (0.47, 2.46)
Other than first remission
(AML, ALL) 1.85 (1.56, 2.21) Insufficient Data
First chronic phase (CML) 0.46 (0.37, 0.57) 0.79 (0.32, 1.97)
Other than first chronic
phase (CML) 1.63 (1.32, 2.01) 2.65 (1.00, 7.04)
Other 1.05 (0.89, 1.24) 1.27 (0.53, 3.03)
LL, acute lymphocytic leukemia; AML, acute myelocytic leuke-
mia; CLL, chronic lymphocytic leukemia; CML, chronic mye-tlocytic leukemia.
26ation. The 95% CIs calculated for the observed/
xpected mortality for each year after the 10th year
ost-BMT included the ratio of 1, suggesting that the
bserved mortality rate is not signiﬁcantly different
rom that expected. The conﬁdence interval is wide
or these estimates based on 2 deaths per year.
Figure 5 shows the survival curves for patients
ndergoing transplantation in different time periods.
statistically signiﬁcant (P  .001) difference in sur-
ival can be seen between patients treated before Sep-
ember 10, 1986 and those treated after that date. The
ong-term survival of those patients undergoing trans-
lantation after September 10, 1986 shows a pattern
imilar to that of the entire cohort (data not shown);
owever, the data have not matured sufﬁciently to
llow us to draw deﬁnite conclusions about this subset
f patients. Only 298 patients (9 of whom later died)
nderwent transplantation after September 10, 1986
nd had more than 6 years of follow-up, and no pa-
ient died with more than 10 years of follow-up. Be-
ore year 10, the observed number of deaths was
reater than expected for this cohort.
mpact of Causes of Death
Causes of death were grouped broadly as trans-
lantation-related (TRM), associated with recurrence
f the underlying disease (relapse), or other causes.
arly TRM contributed predominantly to the very
arly mortality after BMT, with 310 of 517 (60%)
eaths in the ﬁrst year attributed to TRM. Between
he end of the ﬁrst year and the beginning of the sixth
ear, death was most frequently attributed to relapse,
ccurring in 73 of 173 (42%) deaths. Of the 26 pa-
 after BMT
20 25 30
tive 45-day intervals after transplantation.Years
15ients who died after the sixth year, 10 died due to late
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BMT complications, including chronic GvHD(6 pa-
ients; 23%), respiratory failure (3 patients; 13%), and
ate graft failure (1 patient; 4%). Other causes of death
n this group were relapse (8 patients; 31%), secondary
alignancy (7 patients; 27%), and myocardial infarc-
ion (1 patient; 4%).
ISCUSSION
We have described a study evaluating the short-
erm and long-term outcomes of BMT allograft re-
ipients who underwent transplantation in a single
enter. Follow-up of all but 1 of 1387 patients who
nderwent transplantation in 1970–2002 was avail-
ble, thus precluding any inﬂuence of selection bias.
here is a considerable risk of patients dying shortly
Y
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Cyclophosphamide + Frac
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Figure 3. Overall survival of patients alive at
able 4. Mortality Statistics by Year of Follow-Up
Days After
BMT
Year After
BMT
Patients Alive at
Year Start
Deaths Prior to
12/31/2002
-365 0-1 1386 517
65-730 1-2 794 82
30-1095 2-3 669 36
095-1460 3-4 587 31
460-1825 4-5 484 15
825-2190 5-6 417 9
190-2555 6-7 368 5
555-2920 7-8 318 9
920-3285 8-9 277 3
285-3650 9-10 240 4
650-4015 10-11 205 0
015-4380 11-12 171 1
380-4745 12-13 143 1
745-5110 13-14 118 0
110-5475 14-15 99 1
475- 15- 77 2
B&MTfter allogeneic BMT, as indicated by the procedure’s
-year survival rate of approximately 55%. The risk of
eath decreases as patients survive longer after trans-
lantation.
The present study was undertaken to determine
hether long-term survivors of BMT could ever ex-
ect a mortality rate comparable to that of the normal
opulation. Six years was chosen as the cutoff time for
lassifying patients as long-term survivors. This was
ased on a detailed analysis that estimated HRs over
ime. The mortality rate remained relatively constant
or patients once they survived 6 years after BMT, and
pproximately 30% of all deaths were attributable
o causes other than relapse or treatment. Variables
nown to predict short-term survival did not predict
urvival after 6 years. Thus, patients who are at greater
After BMT
20 25 30
sphamide + TBI
d TBI
p=0.27
after transplantation by preparative regimen.
ient-Years
Follow-Up
Expected Number
of Deaths
Observed/Expected
Number of Deaths (95% CI)
1012.57 2.2196 232.92 (213.28, 253.90)
719.79 1.5763 52.02 (41.37, 64.57)
622.77 1.4016 25.68 (17.99, 35.56)
534.89 1.2109 25.60 (17.39, 36.34)
450.44 1.0107 14.84 (8.31, 24.48)
389.60 0.8747 10.29 (4.70, 19.53)
345.99 0.7645 6.54 (2.12, 15.26)
297.06 0.6397 14.07 (6.43, 26.71)
258.56 0.5734 5.23 (1.08, 15.29)
224.42 0.5168 7.74 (2.11, 19.82)
187.85 0.4267 —
157.59 0.3495 2.86 (0.07, 15.94)
130.51 0.2969 3.37 (0.09, 18.77)
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4isk of dying immediately after BMT do not appear to
e at any greater risk once they become long-term
urvivors. Donor gender was the only statistically sig-
iﬁcant predictor of long-term survival; this ﬁnding is
onsistent with the observation by Socie et al. [4] that
ale recipients of BMT from a female donor were at
igniﬁcantly (P .001) higher risk of death more than
years after the transplantation.
Although the mortality rate of BMT patients sta-
ilizes around 6 years after BMT, the rate remains
igher than that of the Canadian normal population.
here is considerable variability in the observed/
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Management of patients with prophylactic cyclo-
porine and the therapeutic use of ganciclovir appear
o be signiﬁcant predictors of overall survival; patients
ho underwent transplantation before September 10,
986 have a worse outcome than those who did so
fter this date. The observed number of deaths among
ong-term survivors undergoing transplantation after
eptember 10, 1986 remains greater than expected;
owever, the numerical value for this subset of pa-
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Long-Term Survival after Blood and Marrow Transplantation
Bients is closer to 1 than for all patients. The number
f patient-years of follow-up is insufﬁcient for a de-
ailed analysis on this subset of patients at this time.
All patients in this cohort underwent BMT at the
ame institution. Generalizations of the survival pat-
ern to other institutions may not be appropriate. The
omparison group for expected number of deaths was
he entire Canadian population, despite the fact that
ost patients were residents of a single Canadian
rovince (Ontario). This choice was made because
here were residents of other provinces in the database
s well and because age- and gender-speciﬁc mortality
ates were publicly available only at a national level,
ot at a provincial level. Finally, all patients were
ensored at December 31, 2002 unless death was
oted. This was due to the completeness of the data-
ase and the belief that all patient deaths would be
ecorded promptly. More than 1 year passed between
ensoring date and data extraction, however; thus,
lthough it is possible that some patients died before
he censoring date and were not recorded, it is be-
ieved to be highly unlikely.
Frequently, patients who undergo BMT question
hether their life expectancy ever becomes equivalent
o that of the normal population and whether the risk
actors at the time of BMT remain risk factors after
ecoming a long-term survivor. This study is the ﬁrst
o attempt to quantify when a BMT patient can be
lassiﬁed as a long-term survivor and to attempt to
nswer these questions. Apparently, a BMT patient
an be considered a long-term survivor after having
ived 6 years post-BMT. The risk of death appears to
evel off at this time, and when death does occur, it is
ore likely attributable to causes not considered re-
ated to BMT. Although the life expectancy of BMT
atients appears to remain lower than that of the
ormal population, the difference appears to decrease
ith increasing survival time. The currently available
ata suggest that this remains true even for patients
ho received GvHD prophylaxis with cyclosporine
B&MTnd had ganciclovir available, although stating a def-
nite conclusion will require longer follow-up. The dif-
erence between transplantation patients and the normal
opulation is apparently even smaller in the most recent
MT patient cohort. Known risk factors for short-
erm survival appear to disappear over time, with only
onor gender appearing to predict survival among
ong-term survivors.
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